BiotaX has developed deep explainable AI models based on system biology that can collect, analyze and predict multiple disease states and calculate optimal interventions supported by cutting-edge meta-genomic AI analysis.
TaxonAI- Novel deep insights Computetional Platform
BiotaX's deep explainable AI models based on system biology can predict multiple disease states and calculate optimal interventions supported by cutting-edge meta-genomic AI analysis platforms.
BiotaX is the only technology platform capable of comprehensive multi-omics solution based on microbiome and system biology. Our patented CustomBiome presents next-generation LBP production technology, which is able to isolate targeted live microbes on the strain level ( TaxonAI Output ) based either on their taxonomy or gene functional BiotaX can package these microbes as customized live biotherapeutic products (LBPs) to fight dysbiosis in a personalized and disease-specific way.
Colorectal Cancer & High Risk Adenoma
A 90% sensitivity for Colorectal Cancer and 40% for High Risk Adenoma (HRA) in Average-Risk Adults is still insufficient! Colorectal cancer is the second-leading cause of cancer-related deaths in the U.S.A Today, one in three adults have not completed the recommended CRC screening even though colorectal cancer is curable if caught early. Our multi-omics test which adds our powerful and proprietary customeBiome platform will be a revolutionary milestone and change the CRC health outcome.
Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma accounts for more than 90% of all pancreatic cancers and its incidence has increased significantly worldwide. Patients with pancreatic ductal adenocarcinoma have a poor outcome and more than 95% of the people affected die from the disease within 12 mo after diagnosis. Surgery is the first-line treatment in the case of resectable neoplasm, but only 20% of patients are candidates for this approach. Early diagnosis is of crucial importance to improve patient outcome; therefore, we are developing the first ever screening test for Pancreatic ductal adenocarcinoma.
Non-Small Cell Lung Cancer Treatment
Immunotherapy (IO) is the use of medicines to help a person’s own immune system to recognize and destroy cancer cells. The immune system uses “checkpoint” proteins on immune cells, which act like switches that turn on/off the immune response. Drugs that target these checkpoints are called checkpoint inhibitors. In addition to checkpoint genes like PD-L1 gene expression, optimizing IO is critical as starting on IO and switching to a targeted therapy can lead to adverse events. Our customeBiome atlas enables actionable IO personalized medicine in NSCLC.
Prof. Naama Geva-Zatorsky
Head of the Microbiome Lab,The Technion, Rappaport Faculty of Medicine, Technion Integrated Cancer Center.Her research combining systems-biology with microbiology and immunology to study the interactions between gut microbes and the host immune system in health and disease. Her Ph.D from the Weizmann Institute, studying systems-biology of protein dynamics in cancer. Her postdoctoral was at Harvard Medical School, studying gut microbiota-host interactions
Co Founder, CEO
Serial entrepreneur with vast experience as founder, senior executive & business manager CEO and Co founder of BrainVu (Acquired in 2018 ). Head of the Alcatel Lucent Digital Multimedia Division (Was Spin-off and acquired by Nantworks in 2014 ). Shay worked both in startups and corporate organizations with a verity of hands-on technology leadership roles
A computational biology & SW architect expert focusing on complex multidisciplinary problems. Prior to BiotaX, Dean was software architect @Technion Data & Knowledge (TDK) Lab - the computer science faculty and developer team lead @Lamm lab - the department of biology , Technion.
Dean holds an M.Sc. in Biology and B.Sc. in both Mathematics and Computer Science from the Technion.
Dean is a recipient of the 2019 Sherman award for distinguished academic achievement in multidisciplinary research.
Advisory Board / Consulting
Assistant Professor Itai Sharon
Migal - Galilee Research Institute
Head of the Computational Microbiology group at Migal.His research focuses on molecular biology techniques along with advanced computational methods and data science approaches to generate and analyze metagenomics and other data. Currently, research in the lab is focused on human-associated microbes and plant-microbiome interactions.
Assistant Professor Elizabeth Half
MD, Rambam Medial Center
A specialist in gastroenterology and hepatology, Director of the Early Detection and Cancer Prevention Unit at Rambam Medical Center, director of the Hereditary Cancer Clinic and the BRCA Carrier Clinic
Assistant Prof Jennifer McQuade,
MD Oncologist MD Anderson
Jennifer L. McQuade, MD, MS, MA is an Assistant Professor and Physician Scientist in Melanoma Medical Oncology. Her research focuses on how lifestyle factors influence melanoma biology and the anti-tumor immune response with the goal of developing novel strategies to improve outcomes in melanoma.
Pharmaceutical Industry Innovation expert across all therapeutic areas, Senior director at a global pharma MNC (Sanofi), Chief Medical Officer and Business Development at MediCane, Venture Capitalist and Investments in the life Sciences ( aMoon)
Strong scientific, clinical, and commercial proficiency in Business Development Orientation
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle Feb 8 2021
Illumina, Inc. (NASDAQ: ILMN) has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator in the U.S. and UK. The global company creation engine, focused on partnering with entrepreneurs to build breakthrough genomics startups, invested in four companies for the second funding cycle of Illumina Accelerator Cambridge, UK and five companies for the twelfth funding cycle of Illumina Accelerator San Francisco Bay Area. The newest companies to join Illumina Accelerator’s portfolio of genomics startups include: BiotaX Labs LTD, a spinoff from Technion Research and Development Foundation (TRDF) Israel, is harnessing the power of the microbiome to diagnose and provide effective, tailored and safe microbial treatments.